AcelRx announces FDA acceptance of NDA for DSUVIA
AcelRx announced the acceptance of its NDA resubmission for DSUVIA™ by the FDA. The FDA considers the DSUVIA NDA resubmission a complete class 2 response to their Oct. 2017 action letter. Therefore, the FDA has assigned a PDUFA goal date of Nov. 3, 2018. May 24, 2018